上海医药(02607)2026年第三季度报告于2026年10月30日发布。报告期内（2026年7月1日至9月30日），公司单季实现营业收入754.94亿元，同比增长2.74%；归属于上市公司股东的净利润为10.82亿元，同比增长57.15%；扣除非经常性损益后净利润为8.97亿元，同比增长49.69%。
上海医药(02607)2026年第三季度报告于2026年10月30日发布。报告期内（2026年7月1日至9月30日），公司单季实现营业收入754.94亿元，同比增长2.74%；归属于上市公司股东的净利润为10.82亿元，同比增长57.15%；扣除非经常性损益后净利润为8.97亿元，同比增长49.69%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.